GDF-15: Can It Be Used as a Biomarker in Acute Cerebrovascular Incidents?
Journal of Personalized Medicine · 01.06.2026 · 16 (6) · 300
DOI: 10.3390/jpm16060300 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Personalized Medicine, online erschienen am 01.06.2026. Verfasst von Areti Kourti und 5 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Biochemistry, AHEPA University Hospital, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, 54124 Th…. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives: Growth differentiation factor-15 (GDF-15) is a protein that belongs to the transforming growth factor beta superfamily and has been found elevated in cases of organ injury such as liver, kidney, heart, and lung, as well as cardiovascular diseases and cancer. Soluble urokinase plasminogen activator receptor (suPAR) is a protein which is expressed mainly on immune cells and endothelial and smooth muscle cells, and is a marker of severity and intensity of inflammation in acute and chronic diseases. The aim of the present study was to compare GDF-15 serum levels between patients with acute cerebrovascular incidents and healthy controls and to investigate the possible correlation of GDF-15 serum levels and inflammatory markers, such as serum C-reactive protein (CRP) and plasma suPAR, in the above-mentioned groups.
Methods
This is a retrospective study. Thirty-one patients were included in the study, with a mean age ± SD of 67 ± 13 years, compared to 18 age-matched healthy controls.
Results
In the patient group a statistically significant positive correlation of serum levels of GDF15 values with suPAR and CRP emerged (rs = 0.516, p = 0.003) and (rs = 0.409, p = 0.022), respectively, and no significant correlation was found in the group of controls (rs = 0.271, p = 0.277) and (rs = 0.423, p = 0.080), respectively.
Conclusions
These findings support the role of inflammation as a key underlying mechanism in acute cerebrovascular injury and suggest that GDF-15 may serve as a valuable adjunct biomarker for assessing disease severity and inflammatory burden.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Laboratory of Biochemistry, AHEPA University Hospital, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece.
ORCID-Profile: Areti Kourti, Kali Makedou
Zitieren
APA
Kourti, A., Keskilidou, E., Skoura, A., Karalazou, P., Thisiadou, K., & Makedou, K. (2026). GDF-15: Can It Be Used as a Biomarker in Acute Cerebrovascular Incidents?. Journal of Personalized Medicine, 16(6), 300. https://doi.org/10.3390/jpm16060300
Vancouver
Kourti A, Keskilidou E, Skoura A, Karalazou P, Thisiadou K, Makedou K. GDF-15: Can It Be Used as a Biomarker in Acute Cerebrovascular Incidents?. Journal of Personalized Medicine. 2026;16(6):300. doi:10.3390/jpm16060300
BibTeX
@article{Kourti2026,
author = {Kourti, Areti and Keskilidou, Eirini and Skoura, Alexandra and Karalazou, Paraskevi and Thisiadou, Katerina and Makedou, Kali},
title = {GDF-15: Can It Be Used as a Biomarker in Acute Cerebrovascular Incidents?},
journal = {Journal of Personalized Medicine},
year = {2026},
volume = {16},
number = {6},
pages = {300},
doi = {10.3390/jpm16060300}
}
EUVIMED